Drug intelligence / Profile preview

Duratil

Development stage: Unknown
Lead developer: GP Pharm
Modality: Peptides
Administration: Subcutaneous

Overview

Duratil is a teriparatide formulation developed by GP Pharma for the treatment of osteoporosis in patients at high risk of fracture. As a recombinant human parathyroid hormone (PTH 1-34) analog, it acts as a PTH receptor agonist. When administered intermittently via subcutaneous injection, it stimulates osteoblastic activity, promoting new bone formation and increasing bone mineral density. It is marketed as a cost-effective generic or biosimilar alternative to the reference teriparatide products, particularly in the Spanish market where it is classified as an Equivalente Farmacéutico Genérico (EFG).

Brand names: Duratil
Other names: teriparatideteriparatida

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on Duratil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Duratil.

Explore the full profile